HK Stock Market Move | LAENA-B(02105) rose more than 6% in the afternoon. LAE102 is expected to achieve high-quality weight control in combination with GLP-1.

LAEKNA-B (02105) rose more than 6% in the afternoon, reaching a 4.87% increase at the time of writing, trading at 14.63 Hong Kong dollars with a turnover of 21.63 million Hong Kong dollars. On the news front, Laekna Pharmaceuticals announced a successful collaboration with Lilly in the United States to complete the Phase I single-dose escalation study of its self-developed selective targeted ActRIIA monoclonal antibody, LAE102. The results showed that after a single injection of LAE102, there was an encouraging dose-dependent trend of muscle growth and fat reduction. LAE102 in combination with GLP-1 receptor agonists can reduce fat and significantly reduce muscle loss caused by the latter, becoming a candidate drug for high-quality weight control. FIRST SHANGHAI released a research report stating that the global next-generation GLP-1 drug development direction is focused on reducing fat and increasing muscle, with LAE102 being one of the potential key solutions. LAE102 has a long patent period and, together with the pipeline LAE103 and LAE123, forms the ActRII target combination, which is expected to become the cornerstone therapy for the next generation of high-quality weight management.